anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In polycystic kidney disease (PKD), microscopic tubules expand into macroscopic cysts. Among the world's most common genetic disorders, PKD is inherited via heterozygous loss-of-function mutations but is theorized to require additional loss of function. To test this, we establish human pluripotent stem cells in allelic series representing four common nonsense mutations, using CRISPR base editing. When differentiated into kidney organoids, homozygous mutants spontaneously form cysts, whereas heterozygous mutants (original or base corrected) express no phenotype. Using these, we identify eukaryotic ribosomal selective glycosides (ERSGs) as PKD therapeutics enabling ribosomal readthrough of these same nonsense mutations. Two different ERSGs not only prevent cyst initiation but also limit growth of pre-formed cysts by partially restoring polycystin expression. Furthermore, glycosides accumulate in cyst epithelia in organoids and mice. Our findings define the human polycystin threshold as a surmountable drug target for pharmacological or gene therapy interventions, with relevance for understanding disease mechanisms and future clinical trials.
Sports medicine is a multidisciplinary comprehensive discipline, and is positioned as a secondary discipline in the country. It is a clinical application-based discipline that combines medicine and sports to solve sports-related diseases from a medical perspective. The treatment range is centered on the joints. The main treatment method is arthroscopic technology to solve sports-related injuries. Together with postoperative rehabilitation, the goal is to achieve the greatest recovery of motor function. This project is planned to be based on the medical insurance database collected by the China Health Insurance Research Association (CHIRA). As a national academic research institution, CHIRA collects medical insurance patient data, covering more than 20 provinces across the country. The data of more than 60 municipalities, provincial capitals, and prefecture-level cities are unique and authoritative in my country. Based on the CHIRA database, big data analysis for Chinese sports medicine patients, starting from the names of medical institutions, admission/discharge diagnosis and classification of medical items, etc., to investigate the development trend of arthroscopic surgery in China and understand my country's arthroscopic diseases The distribution characteristics and changing trends of the quantity.
Obesity may lead to pulmonary dysfunction through complex and incompletely understood cellular and biochemical effects. Altered lung lipid metabolism has been identified as a potential mechanism of lung dysfunction in obesity. Although murine models of obesity demonstrate changes in pulmonary surfactant phospholipid composition and function, data in humans are lacking. We measured untargeted shotgun lipidomes in two bronchoalveolar lavages (BALs) from apical and anteromedial pulmonary subsegments of 14 adult subjects (7 males and 7 females) with body mass indexes (BMIs) ranging from 24.3 to 50.9 kg/m2. The lipidome composition was characterized at the class, species, and fatty acyl/alkyl level using total lipid molecular ion signal intensities normalized to BAL protein concentration and epithelial lining fluid volumes. Multivariate analyses were conducted to identify potential changes with increasing BMI. The alveolar lipidomes contained the expected composition of surfactant-associated phospholipids, sphingolipids, and sterols in addition to cardiolipin and intracellular signaling lipid species. No significant differences in lipidomes were detected between the two BAL regions. Though a small number of lipid species were associated with BMI in multivariate analyses, no robust differences in lipidome composition or specific lipid species were identified over the range of body habitus. The magnitude of obesity alone does not substantially alter the alveolar lipidome in patients without lung disease. Differences in lung function in patients with obesity and no lung disease are unlikely related to changes in alveolar lipid composition.NEW & NOTEWORTHY Altered lung lipid metabolism has been identified as a potential mechanism of lung dysfunction in obesity, but data in humans are lacking. We measured the alveolar lipidome in bronchoalveolar lavages from subjects with healthy lungs with a wide range of body mass index. There were no differences in lipidome composition in association with the magnitude of obesity. In patients with healthy lungs, obesity alone does not alter the alveolar lipidome.
The control group (G1) will be composed of puerperal women over 18 years of age attended by Lucila Balalai Municipal Maternity in Londrina. Recruitment will be done through a chart review, which will include single-fetus primiparous that delivered on full term without intercurrence (between 37 and 42 weeks).
Ten subjects will be randomly assigned in a ratio of 4:1 to receive 5 mg of PA3670 tablets or PA3670 placebo tablets. They will be administered a single dose and observed for four days.
The invention relates to a cyclic RNA, a cyclic RNA drug with an anti-tumor effect and application thereof, in particular to a preparation method of a cyclic p53 sequence and a cyclic p53 bone-loaded targeted Extracellular Vesicles (EVs) and application thereof, belonging to the technical field of medicines. The circular RNA is a circular RNA of classical oncogene p53 (circp, hsa_circ_ 0041947). In vivo and in vitro experiments show that the drug delivery system has good myeloma targeting property and shows remarkable tumor inhibition effect. The present invention has found that hsa_circ_0041947 can be divided into two categories, wild type and mutant. The wild type sequence is consistent with the non-mutant P53 nucleotide sequence, the mutant is the 148 th nucleotide CGC mutated into CAC, and the mutant sequence has no anti-tumor effect. The invention discovers that the anti-tumor circp sequence and engineering circp53-EVs can be effectively used for treating wild type and mutant myeloma, and provides a nucleic acid drug delivery system with good targeting, high biological safety and definite tumor inhibiting effect for treating myeloma, colon cancer and other tumors.
PURPOSE OF REVIEW: Sarcopenia is a wasting disease, mostly age-related in which muscle strength and mass decline, such as physical performance. With aging, both lower dietary protein intake and anabolic resistance lead to sarcopenia. Moreover, aging and sarcopenia display low-grade inflammation, which also worsen muscle condition. In this review, we focused on these two main targets to study dietary strategies.
RECENT FINDINGS: The better understanding in mechanisms involved in sarcopenia helps building combined dietary approaches including physical activity that would slow the disease progression. New approaches include better understanding in the choice of quality proteins, their amount and schedule and the association with antioxidative nutrients.
SUMMARY: First, anabolic resistance can be countered by increasing significantly protein intake. If increasing amount remains insufficient, the evenly delivery protein schedule provides interesting results on muscle strength. Quality of protein is also to consider for decreasing risk for sarcopenia, because varying sources of proteins appears relevant with increasing plant-based proteins ratio. Although new techniques have been developed, as plant-based proteins display a lower availability, we need to ensure an adapted overall amount of proteins. Finally, specific enrichment with leucine from whey protein remains the dietary combined approach most studied and studies on citrulline provide interesting results. As cofactor at the edge between anabolic and antioxidative properties, vitamin D supplementation is to recommend. Antioxidative dietary strategies include both fibers, vitamins, micronutrients and polyphenols from various sources for positive effects on physical performance. The ω 3 -polyunsaturated fatty acids also display positive modifications on body composition. Gut microbiota modifiers, such as prebiotics, are promising pathways to improve muscle mass and function and body composition in sarcopenic patients. Nutritional interventions could be enhanced by combination with physical activity on sarcopenia. In healthy older adults, promoting change in lifestyle to get near a Mediterranean diet could be one of the best options. In sarcopenia adults in which lifestyle changes appears unprobable, specific enrichement potentialized with physical activity will help in the struggle against sarcopenia. Longitudinal data are lacking, which makes it hard to draw strong conclusions. However, the effects of a physical activity combined with a set of nutrition interventions on sarcopenia seems promising.
The breadth and depth at which cancer models are interrogated contribute to the successful clinical translation of drug discovery efforts. In colorectal cancer (CRC), model availability is limited by a dearth of large-scale collections of patient-derived xenografts (PDXs) and paired tumoroids from metastatic disease, where experimental therapies are typically tested. Here we introduce XENTURION, an open-science resource offering a platform of 128 PDX models from patients with metastatic CRC, along with matched PDX-derived tumoroids. Multidimensional omics analyses indicate that tumoroids retain extensive molecular fidelity with parental PDXs. A tumoroid-based trial with the anti-EGFR antibody cetuximab reveals variable sensitivities that are consistent with clinical response biomarkers, mirror tumor growth changes in matched PDXs, and recapitulate EGFR genetic deletion outcomes. Inhibition of adaptive signals upregulated by EGFR blockade increases the magnitude of cetuximab response. These findings illustrate the potential of large living biobanks, providing avenues for molecularly informed preclinical research in oncology.
Substances in the solid state intended for application toe the skin, comprising an active agent, (I) which has a desired effect after applicaton to the skin, opt. fillers and a binder which contains or consists exclusively of a wax-, fat- or oil-like substance (II), the overall binder being soluble in water. USE/ADVANTAGE - The prods. are esp. useful for the prodn. of stick-type applicators of the type used for application of lipstick, eyeliner, eyeshadow, makeup, insect repellents, sun protection agents, cosmetics, etc. to the skin. The binder give stick type prods. with high mechanical strength, shear resistance, drop break resistance, and resistance to high temps.  The active substance (I) may be e.g. (in)organic cosmetic pigments, pearl gloss agents, metal powders, physiologically active substances such as painkillers (acetyl salicylic acid) antiphlogistic and cooling agents (bisabolol, camomile, menthol), disinfecting, antiobiotic substances, etc.
The present disclosure relates to the use of contact lenses for treating one or more ophthalmologic conditions. In some embodiments, the contact lenses may be used to treat presbyopia, induced myopia, computer vision syndrome (CVS), insufficient accommodation, or a condition associated with insufficient accommodation. The contact lens may include a number of regions having different geometries (e.g., curvature, width, diameter) depending on the flattest keratonomy of the cornea to achieve a suitable fit. For example, the contact lens may include an optic zone surrounded by an inner peripheral region and an outer peripheral region surrounding the inner peripheral region, each exhibiting varying degrees of curvature. The fitted contact lens may be selected based on a measured sagittal depth and/or eccentricity of the cornea. When fitted, an appropriate amount of fluid may accumulate between the cornea of the eye and the contact lens. In addition, the lens may exhibit a sufficient amount of apical clearance such that when the wearer blinks, the lens moves no more than 1 mm on the eye. Further, the lens and the eye may be mutually structured such that bubbles greater than 0.5 mm in diameter are prevented from forming between the contact lens and the eye. The contact lens may be used in combination with a suitable bioactive agent providing for enhanced visual correction.
An RCT was conducted in six European centres: London (UK), Ulm-Guenzburg (Germany), Rimini (Italy), Zurich (Switzerland), Groningen (the Netherlands) and Sofia (Bulgaria). Patients were included if they had a diagnosis of SMI (psychotic illness including bipolar disorder), were aged 18 to retirement age, had been ill and had major role dysfunction for at least two years, were living in the community at baseline, had not been in competitive employment in the preceding year and expressed the desire to enter competitive employment. They were randomly allocated to receive either IPS or the 'Vocational Service' (control service). Given the need to consider the impact of gender and work history on vocational outcomes (20), service allocation was stratified by centre, gender and work history (more or less than a month's competitive employment in the five years prior to baseline). Randomisation was conducted centrally using MINIM Version 1.5. A researcher at each centre recruited the patients, submitted them to the statistician for randomisation and received the allocation by email. The allocation sequence was concealed until the services had been assigned, but it was not possible for patients, professionals or researchers to be blind to service allocation thereafter.
Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving response may continue treatment.
Aortic valve stenosis is a common condition that requires an anesthesiologist's in-depth knowledge of the pathophysiology, diagnostics and perioperative features of the disease. A newly diagnosed aortic valve stenosis is often initially identified from the anamnesis (dyspnea, syncope, angina pectoris) or a suspicious auscultation finding during the anesthesiologist's preoperative assessment. Interdisciplinary collaboration is essential to ensure the optimal management of these patients in the perioperative setting. An accurate anamnesis and examination during the preoperative assessment are crucial to select the most suitable anesthetic approach. Additionally, a precise understanding of the hemodynamic peculiarities associated with aortic valve stenosis is necessary. After a short summary of the overall pathophysiology of aortic valve stenosis, this review article focuses on the specific anesthetic considerations, risk factors for complications, and the perioperative management for noncardiac surgery in patients with aortic valve stenosis.
For refractory NMO patients aged 18-55, the initial dose 12 mg/m2 mitoxantrone was administered over a five day course every 3 months for 2 years (a total of eight courses). The initial dose was reduced to 9 mg/m2 if the preinfusion white-blood-cell count was 3.0-3.99 ×109/L,and to 6 mg/m2 if the white-blood-cell count was 2.0-2.99 ×109/L. No infusion if the white-blood-cell count was less than 2.0×109/L. The initial dose was reduced to 10 mg/m2 for nonhaematological toxic effects of WHO grade 2-3. Subsequent dose after 3 month was reduced to 10 mg/m2 for infections that occurred within 3 weeks of a previous infusion accompanied by a white-blood-cell count below 2×109/L, or to 8 mg/m2 for infections accompanied by white-blood-cell count of less than 1×109/L.
PURPOSE: A composition containing cineole for preventing and treating metabolic syndrome is provided to enhance HDL function and to reduce lipid. CONSTITUTION: A composition for preventing or treating metabolic syndrome contains cineole as an active ingredient. Cineole has antioxidative or anti-inflammatory function and is denoted by chemical formula 1. Cineole has a molecular structure of 1,3,3-trimethyl-2-oxabicyclo[2,2,2]octane. Cineole has fragrant flavor and cool taste. A pharmaceutical composition for preventing or treating metabolic syndrome contains cineole as an active ingredient. A health food for preventing or treating metabolic syndrome contains cineole as an active ingredient. A cosmetic composition for preventing or treating metabolic syndrome contains cineole as an active ingredient.
Serious cases of herpes zoster have occurred with dimethyl fumarate, including disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, and herpes zoster meningomyelitis. These events may occur at any time during treatment. Monitor patients on dimethyl fumarate for signs and symptoms of herpes zoster. If herpes zoster occurs, appropriate treatment for herpes zoster should be administered. 

Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral (herpes simplex virus, West Nile virus, cytomegalovirus), fungal (Candida and Aspergillus), and bacterial (Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis) infections. These infections have been reported in patients with reduced absolute lymphocyte counts (ALC) as well as in patients with normal ALC. These infections have affected the brain, meninges, spinal cord, gastrointestinal tract, lungs, skin, eye, and ear. Patients with symptoms and signs consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment. 

Consider withholding dimethyl fumarate delayed-release capsules treatment in patients with herpes zoster or other serious infections until the infection has resolved [see Adverse Reactions (6.2)].
Hepatic tumors seldom occur in the perinatal period. They comprise approximately 5% of the total neoplasms of various types occurring in the fetus and neonate. Infantile hemangioendothelioma is the leading primary hepatic tumor followed by hepatoblastoma. It should be mentioned that alpha-fetoprotein (AFP) is highly elevated during the first several months after birth even in normal infants, thus the diagnostic value of AFP is limited for infantile patients with hepatic tumors. This study is a retrospective-prospective design by West China Hospital, Sichuan University, including clinical data and radiological images. A retrospective database was enrolled for patients with definite histological diagnosis and available magnetic resonance imaging (MRI) images from June 2010 and December 2020. The investigators have constructed a deep learning radiomics diagnostic model on this retrospective cohort and validated it internally. A prospective cohort would recruit infantile patients diagnosed as liver tumor since January 2021. The proposed deep learning model would also be validated in this prospective cohort externally. The established model would be able to assist diagnosis for hepatic tumor in infants.
The invention discloses a Tibetan medicine for treating acquired immunodeficiency syndrome. The Tibetan medicine consists of an active component or the active component and the pharmaceutically acceptable adjuvants. The active component is prepared from ouqu, brenstone, herba aconiti, olibanum and fructus chebulae according to certain weight ratio. The Tibetan medicine can be prepared into any frequently-used orally taken preparation. The Tibetan medicine has the effects of diminishing inflammation, sterilizing,, clearing away toxic materials and removing damness. The major functions of the medicine include treating erysipelas, podagra, rheumatism, rheumatoid arthritis, edema, hydropsy, ascites aeipathia, cephalomeningitis, and eighteen pestilences that have been called in the Tibetan medicine. From the perspective of the Tibetan medicine, all pestilences are viruses and bacteria, and any pestilence without virus and bacteria cannot be caused.
Acute ischemic stroke (AIS) is one of the main causes of death and disability and thereby the third leading cause of loss of quality adjusted life years. For patients with an AIS due to an occlusion of the large vessels of the anterior circulation, endovascular therapy (EVT) has become a treatment standard. 20-40% of all AIS patients have occlusions of smaller vessels and present with a more distal isolated Medium Vessel Occlusion (MeVO). The primary objective of this randomized trial is to determine whether patients experiencing an AIS due to an isolated medium vessel occlusion have superior functional outcome (measured with the Modified Rankin Scale "mRS" at 90 days) when treated with EVT plus best medical treatment (BMT) compared to patients treated with BMT alone. In this trial, all commercially available, CE-certified revascularisation devices (i.e. stent-retriever, aspiration catheters and balloon guide catheters) can be used for EVT. All established techniques for the endovascular treatment of AIS patients are permitted and all decisions regarding treatment technique and choice of devices and/or medications are made solely by the treating physician.
Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 28 days. Throughout the 28 day treatment period, dosage will be adjusted based on serum potassium and creatine levels from blood draws done on Day 12. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic ("not tied to a specific vendor") program.
Aripiprazole produced retinal degeneration in albino rats in a 26-week chronic toxicity study at a dose of 60 mg/kg and in a 2-year carcinogenicity study at doses of 40 mg/kg and 60 mg/kg. The 40 mg/kg and 60 mg/kg doses are 13 times and 19 times the maximum recommended human dose (MRHD) based on mg/m and 7 times to 14 times human exposure at MRHD based on AUC. Evaluation of the retinas of albino mice and of monkeys did not reveal evidence of retinal degeneration. Additional studies to further evaluate the mechanism have not been performed. The relevance of this finding to human risk is unknown. 2
PURPOSE: A composition containing insect glycosaminoglycan is provided to prevent or treat fatty liver or hyperlipidemia. CONSTITUTION: A composition for preventing and treating fatty liver contains insect-derived glycosaminoglycan as an active ingredient. The insect is selected from the group consisting of silkworm, Gymnopleurus mopsus, Paecilomyces sinclairii, Velarifictorus asperses, Bombus ignites, Bomyx mori, Poecilocoris lewisi, and Protaetis brevitarsis. The fatty liver is alcoholic or non-alcoholic fatty liver. A composition for preventing and treating hyperlipidemia contains insect-derived glycosaminoglycan as an active ingredient. The compositions contain an insect extract as an active ingredient.